CRX Cyprotex

TIDMCRX

RNS Number : 4611X

Cyprotex PLC

19 November 2014

Cyprotex PLC

("Cyprotex" or "the Company")

Director dealing

The Company received notification that Ralph Stephen Harris, Non-executive Director of the Company, acquired 10,000 ordinary shares in the Company on 18 November 2014 at a price of 39 pence per share. As a result of this purchase Mr. Harris has a beneficial interest in 210,514 ordinary shares in the Company representing approximately 0.94 per cent. of the Company's total voting rights.

 
 
 
 
 
   Cyprotex PLC 
                                           Tel : +44 (0)1625 
                                           505 100 
 Dr Anthony Baxter, Chief Executive 
  Officer 
 John Dootson, Chief Financial Officer 
 Mark Warburton, Chief Operating 
  Officer and Legal Counsel 
 ir@cyprotex.com                         www.cyprotex.com 
 
 N + 1 Singer (NOMAD and broker to       Tel : +44 (0)20 
  Cyprotex)                               7496 3000 
 Shaun Dobson 
 shaun.dobson@n1singer.com 
 Jen Boorer 
 jen.boorer@n1singer.com                 www.nplus1singer.com 
 
 

About Cyprotex PLC

Cyprotex is listed on the AIM market of the London Stock Exchange (CRX). It has sites in Macclesfield, near Manchester in the UK, Watertown, MA and Kalamazoo, MI in the US. The Company was established in 1999 and works with more than 1,000 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services, extending from early drug discovery through to IND submission. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics and chemical industries. The Company's core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr(R) toxicity prediction technology, predictive modelling using PBPK and QSAR techniques, including Cloe(R) PK for in vivo PK prediction, and a range of skin, ocular and endocrine disruption services. For more information, see www.cyprotex.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSXKLFFZFFLFBZ

Cyprotex (LSE:CRX)
Historical Stock Chart
From Mar 2024 to Apr 2024

Cyprotex (LSE:CRX)
Historical Stock Chart
From Apr 2023 to Apr 2024